Tcw Group Inc Spring Works Therapeutics, Inc. Transaction History

Tcw Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 19, 2022	BUY	$48.97 - $65.46 $538 - $720	11 Added 0.01%	74,671 $4.21 Million
Q4 2021 Jan 26, 2022	SELL	$53.3 - $75.84 $717,098 - $1.02 Million	-13,454 Reduced 15.27%	74,660 $4.63 Million
Q2 2021 Jul 23, 2021	SELL	$67.45 - $85.63 $813,042 - $1.03 Million	-12,054 Reduced 12.03%	88,114 $7.26 Million
Q1 2021 May 05, 2021	SELL	$65.1 - $93.59 $1.46 Million - $2.1 Million	-22,491 Reduced 18.34%	100,168 $7.37 Million
Q4 2020 Feb 02, 2021	BUY	$48.36 - $77.92 $1.01 Million - $1.63 Million	20,861 Added 20.49%	122,659 $8.9 Million
Q3 2020 Oct 30, 2020	SELL	$36.14 - $51.99 $716,909 - $1.03 Million	-19,837 Reduced 16.31%	101,798 $4.85 Million
Q2 2020 Aug 05, 2020	SELL	$22.98 - $48.57 $25,806 - $54,544	-1,123 Reduced 0.91%	121,635 $5.11 Million
Q1 2020 May 05, 2020	BUY	$20.44 - $41.21 $2.51 Million - $5.06 Million	122,758 New	122,758 $3.32 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Tcw Group Inc, based on Form 13F filings with the SEC.

Stay updated on Tcw Group Inc with notifications on news.